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 Thomas Hobson was a livery stable owner in Cambridge, England, in the 17th 
century who had an extensive stable of over 40 horses and ran a thriving horse rental 
business. His customers believed that, upon entry, they would be given their choice of 
mounts, when in fact he offered them no choice: Hobson required that all his 
customers choose the horse in the stall closest to the door or have no horse at all. 
Quite literally, they had no choice but ‘Hobson's choice’. Similarly, in percutaneous 
coronary intervention (PCI), adjunctive pharmacotherapy with platelet inhibitors and 
anticoagulant regimes have improved clinical outcomes through a reduction in 
ischemic events including stent thrombosis 1-3, albeit at the expense of increased 
bleeding complications 4. Whilst the delivery of antiplatelet agents and anticoagulant 
regimes can be personalized at an individual patient level in an attempt to balance the 
reduction in ischemic risk whilst minimizing the increased risk of major bleeding, like 
Hobson’s choice in the 17th century, there is currently no option to avoid these agents 
altogether in PCI in high bleeding risk patients. Thus, in general, it is either 
'antiplatelet inhibition or no PCI', a 21st century interventional cardiologist’s 
manifestation of Hobson’s choice. 
 Thrombocytopenia is not uncommon in patients undergoing PCI with a 
reported prevalence of around 6% in a pooled analysis of the ACUITY and 
HORIZONS-AMI trials, 5 with up to 7% of elective patients 6 and 13% of patients 
with acute coronary syndrome (ACS) developing new thrombocytopenia during their 
hospitalization. 7 Patients with thrombocytopenia tend to be older 5, 7, 8, have more 
extensive coronary disease 5 and a greater prevalence of adverse clinical 
characteristics including renal failure 9, diabetes mellitus5, 7, 8 and prior PCI or CABG 
5, 8. Furthermore, thrombocytopenia is a recognised side effect of treatment with 
glycoprotein IIb/IIIa inhibitors (GP IIb/IIIA) 10 or heparin 11 through immune-
mediated mechanisms 8, 12.  
 In this current issue of Circulation: Cardiovascular Interventions, using a 
pooled, patient-level analysis derived from over 23,000 participants from the 
CHAMPION trials, Groves et al. 13 report that 0.8% of patients undergoing PCI 
develop thrombocytopenia.  GpIIb/IIIa use, age, diabetes, hyperlipidemia, and prior 
CABG were all independently associated with acquired thrombocytopenia; with 
GPIIb/IIIa use the strongest predictor (OR 2.85, 95% CI 2.07 to 3.94; P<0.001). 
Importantly, Cangrelor treatment itself had no effect on the incidence of 
thrombocytopenia irrespective of whether a GPIIb/IIIa was used.  
 In line with previous work that has reported adverse clinical outcomes 
associated with acquired thrombocytopenia following PCI 6, 8, 14, 15, the current study 
reports that patients who developed thrombocytopenia after PCI had a 13-fold 
independent increased risk of GUSTO severe bleeding and a 3-fold increased risk of 
stent thrombosis at 48 hours. Further, there was a 3- and 5-fold increased adjusted risk 
of 30-day MACE and mortality, respectively in the thrombocytopenia group. Even in 
the patients who did not sustain a major bleeding complication within 48 hours, 
thrombocytopenia remained independently associated with increased risk of MACE at 
30 days. The latter is almost certainly under-appreciated and of considerable clinical 
relevance. 
 Whilst such increased risks associated with thrombocytopenia are, in general, 
well known, less is known about the optimal management of patients who either have 
prevalent thrombocytopenia or develop it following treatment. Patients with 
thrombocytopenia are routinely excluded from landmark antiplatelet trials such as 
TRITON-TIMI 38 16, PLATO 17 and consequently the safety of contemporary 
antiplatelet therapies used in ACS patients is not well defined. Specifically, there are 
currently no guideline recommendations or consensus reports to guide interventionists 
on the management of PCI patients with thrombocytopenia.  
 The authors have previously published an opinion piece regarding the 
management of PCI patients with thrombocytopenia, and have included management 
recommendations made according to the clinical setting (elective and ACS) and the 
severity of thrombocytopenia.18 These recommendations include identification and 
correction of any reversible causes of thrombocytopenia, and minimization of 
bleeding risk including avoidance of non-steroidal anti-inflammatory drugs, 
GPIIb/IIIa inhibitors and utilization of proton pump inhibitors.  
 In ACS patients who are not undergoing PCI, the authors recommend that 
clopidogrel monotherapy should be considered if platelet count is <100 x109/L but 
>50x109/L, in the absence of bleeding. In contrast, in those patients with a platelet 
count <50 x 109/L or in the setting of active bleeding, the authors advise stopping all 
antiplatelet therapy and avoiding PCI altogether. In ACS patients with a platelet count 
>50 x 109/L undergoing PCI, recommendations include adopting a transradial 
approach, restricting DAPT therapy to 1-month post-stent and using second 
generation DES rather than BMS. Finally, in patients with stable coronary artery 
disease, the authors suggest stopping antiplatelet therapy and avoiding PCI in patients 
with a platelet count <50x109/L whilst in those patients with a platelet count >50 x 
109/L and <100 x 109/L, clopidogrel monotherapy and a proton pump inhibitor is 
recommended. If a patient’s symptoms persist despite optimal medical therapy, the 
risks should be weighed against the benefits of proceeding with an invasive strategy 
on an individual basis.  
 The data presented remind operators regarding the importance of the challenge 
we face, on behalf of our patients, in the management of thrombocytopenia. 
Specifically, we face 2 very different clinical scenarios: firstly, the thrombocytopenic 
patient in front of us in whom PCI is otherwise the optimal revascularization strategy, 
and second, the post PCI patient who develops thrombocytopenia. In the first scenario, 
our choices include avoiding PCI altogether, and modification of the intensity and 
duration of antiplatelet therapy, although it is common to ignore a degree of 
thrombocytopenia completely. In post PCI acquired thrombocytopenia, our 
management depends upon the level of the drop, whether the low platelet count is 
accompanied by dysfunction of those platelets that are present, and, of course, the 
actual or theoretical bleeding risk. Little, above and beyond common sense and 
experience-based judgement, helps to inform our management decisions in such 
circumstances, although modification of the intensity and duration of antiplatelet 
therapy is foremost in our armory. There are currently no risk scores to predict the 
development of thrombocytopenia post PCI, and the non-modifiable independent 
predictors of developing thrombocytopenia identified in the current study such as age, 
prior CABG and diabetes are non-specific and feature in most risk scores for adverse 
outcomes for both ischemic and bleeding risk. As such, they offer little value as the 
basis for thrombocytopenia avoidance strategies.  
There is one exception. In the current study use of GpIIb/IIIa inhibitors was 
reported to be the strongest predictor of post PCI thrombocytopenia and this 
represents an important modifiable risk factor. The use of GPIIb/IIIa inhibitors in PCI 
has fallen dramatically since peak period in the 1990s and early 2000s following 
randomized trials such as EPILOG and EPISTENT, in which such agents were 
routinely used for large patient subgroups. Their use in contemporary practice has 
declined due to a number of factors including improved PCI technique, stent 
technology and more potent oral P2Y12 inhibitors. Nevertheless, they are still used in 
cases where there is perceived to be high ischemic risk, significant thrombotic burden 
or in bailout for cases of slow flow / no reflow. Data derived from the CHAMPION 
trials have shown that Cangrelor reduces the requirement for bail out GpIIb/IIIa 
inhibitors in PCI 19 and so may reduce the requirement for GpIIb/IIIa inhibitors 
further in contemporary practice.  
 Groves et al have provided interventionalists with a timely reminder of the 
outcome risks associated with the acquisition of thrombocytopenia after PCI. The 
important observation that this risk of adverse outcome extends beyond the index 
admission is particularly valuable. Avoiding GPIIbIIIa inhibitors wherever possible 
emerges as a clear-cut message. Our response to the development of 
thrombocytopenia post PCI in our patients should be based upon common sense and 
experience. Specifically, we should seek factors that may be causing or exacerbating 
the low platelet count, detect evidence of actual bleeding and estimate theoretical 
bleeding risk, and then make a bespoke and considered judgement about the need to 
compromise on the intensity and duration of our proposed ongoing dual antiplatelet 
therapy.  
Our management plan should be informed by discussion with hematology 
specialists, who have an important role in helping to diagnose some potential causes 
such as heparin-induced thrombocytopenia.  Prophylactic platelet transfusions should 
be avoided since they rarely raise platelet counts and can precipitate thrombosis 20 
although may be necessary in cases where significant bleeding complications occur. 
However, it is important for the experienced interventionalist to understand that their 
clinical experience of post PCI thrombocytopenia will be greater than that of a clinical 
hematologist in most circumstances, so a high level approach that takes into account 
all factors remains important.  
How patients who develop thrombocytopenia with no immediate bleeding 
complications should be managed remains unclear? The current study shows that 
these patients are at significantly increased risk of both bleeding and thrombotic 
complications and discontinuing antiplatelet therapy to a single antiplatelet in such 
cases would further increase the already elevated risk of thrombotic complications. 
Alternatively, continuing potent newer antiplatelet agents may potentiate the already 
elevated bleeding risk in this cohort, although the safety and clinical outcomes 
associated with switching to clopidogrel in such situations is unclear. In patients who 
have no active bleeding watchful waiting is often the dominant management strategy, 
and any theoretical choices related to modifying antiplatelet therapy in these 
circumstances are not informed by any hard data. It is clear, however, that we should 
reject the choice apparently offered to us by Hobson in these patients and manage 
them in a personalized fashion that includes several options regarding the 
modification of their dual antiplatelet therapy intensity and duration. 
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